MINUTES FOR THE BIOSAFETY COMMITTEE

Thursday December 11, 2025 Email Meeting

PRESENT: Arrigo "Ricky" De Benedetti, Ph.D., Chairman.

Christopher Schmoutz, Ph.D., Vice-Chairman

Stephanie Ander, Ph.D.	Ana Maria Dragoi, Ph.D.
Jessica Esparza, Ph.D.	Omar Franco, M.D., Ph.D
Hongyan Guo, Ph.D.	Sarah Harold, B.S.
Seong Kim, Ph.D	Demonzo Mcginnis,B.S.(BSO)
Rebecca Murphy, Ph.D.	Hugh Price, DVM
Krista Queen, Ph.D., Exe. Dir. R.A.	Krista Rodgers, Ph.D.
Xinggui Shen, Ph.D.	Hong Sun, Ph.D.
Tousif Sultan, Ph.D	Vesna Tesic, Ph.D.

ABSENT: Ashley Krukowsky, (OSP)
Michael Stroud, B.S., Safety

I. **MEETING CALLED TO ORDER:** The meeting called December 11, 2025 with a quorum of 16 voting members.

II. **Approval of Minutes from the previous meeting.** Minutes November 13, 2025

III. **NEW PROTOCOLS TO BE CONSIDERED:** None

IV. **TABLED PROTOCOLS WITH MODIFICATIONS REQUIRED:**
The sponsors of both clinical trials are requesting Biosafety Protocols. The committee determined more time was required to adequately review the protocols and both were **TABLED with MODIFICATIONS REQUIRED** by unanimous vote. Since the November meeting complete reviews were sent to the PI and revisions will not require a FULL Committee Review.

B26-009 – Hematology/Oncology – Clinical Trial:
A Phase 3 Study of a arlocabtagene autoleucel, a GPRC5D-directed CAR T Cell Therapy (Quintessential 2 CA 088 clinical trial) in Participants with Relapsed or Refractory Multiple Myeloma and Refractory to Lenalidomide.

B26-010 – Hematology/Oncology – Clinical Trial:
A phase 2, open-label, multicenter study of MB-105 in patients with CD5 positive (CD5+) relapsed / refractory T-cell lymphoma (r/r TCL).

V. CONTINGENT APPROVALS:

B25-007 –To date the has been no response to the committee's comments. She plans to submit her BSL3 revisions at a later date.

B26-004 – CONTINGENT APPROVAL MODIFICATIONS REQUIRED by unanimous vote with a quorum present. The PI has responded to the committee's comments. The CORE Director approved the work to be conducted in the CORE facility and the protocol was moved to the **FULLY APPROVED category**.

VI. TERMINATIONS: None

VII. Old Business: None

VIII. NEW BUSINESS:

B18-001 – CORE Research Facility – The CORE is adding the CMIT/CPX Mass Spec Lab space located in the BRI Electrical power plant to the Research CORE Facility Biosafety protocol and lab personnel. Please note that this lab has no room number assigned to it.

IX. ANNUAL RENEWALS: Fully approved by unanimous vote:

B95-202/Biochemistry
B97-209/OBGYN
B99-022/Microbiology
B06-009/Microbiology
B06-017/Pharmacology
B08-007/Maxillofacial/Oral Surgery
B10-001/Microbiology
B10-007/Biochemistry
B12-008/Anatomy
B15-007/Biochemistry
B19-007/Physiology
B21-001/Physiology
B22-001/Neurology
B23-001/Pathology

X. NON-RESPONDER ANNUAL RENEWALS:

B23-001/Pathology – The PI submitted the annual renewal to the December meeting.

XI. ADD/DELETE MEMOS: All listed completed training and were approved by unanimous vote unless indicated.

B18-001 – CORE Mass Spec. Personnel, training complete.
B20-006 – Physiology
ADD: MSRP Students, training complete.
B22-001 – Neurology
ADD: Postdoc, training complete.

B23-001 – Pathology
ADD: Graduate Student, training complete.

XII. **Contingent ADD MEMOS:** Contingent until training is complete.
B21-002/Pathology
ADD: Resident **(training incomplete)**

Adjourn:

Respectfully submitted:

Sarah Harold
_____
Sarah Harold, B.S., Coordinator

Approved:
Arrigo De Benedetti
Arrigo De Benedetti (Feb 23, 2026 13:31:05 CST)
_____
Arrigo DeBenedetti, Ph.D.
Chair, Biosafety Committee

AGENDA FOR THE BIOSAFETY COMMITTEE
Thursday January 29, 2026

FROM: Arrigo "Ricky" De Benedetti, Ph.D., Chair
Christopher Schmoutz, Ph.D., Vice–Chair

TO:
Stephanie Ander, Ph.D.
Jessica Esparza, Ph.D
Monica Cartelle Gestal, Ph.D
Sarah Harold, B.S., Ex-Officio
Ashley Krukowsky, (OSP) Ex-Officio
Rebecca Murphy, Ph.D.
Krista Queen, Ph.D., Ex-Officio
Xinggui Shen, Ph.D.
Tousif Sultan, Ph.D.
Vesna Tesic, Ph.D.
Ana Maria Dragoi, Ph.D.
Omar Franco, M.D., Ph.D.
Hongyan, Guo, Ph.D.
Seong Kim, Ph.D.
DeMonzo Mcginnis, B.S. (BSO)
V. Hugh Price, DVM
Krista Rodgers, Ph.D.
Michael Stroud, B.S. Director of Safety
Hong Sun, Ph.D.

Meeting called to order:

I. Approval of Minutes from previous meeting. *December 11, 2025*

II. New Protocols to be considered:

B25-007 – Dr. Stephanie Ander/Microbiology – MOLECULAR PATHOGENESIS, IMMUNITY, AND ECOLOGY OF ARTHROPOD-BORNE BSL3 VIRUSES. This protocol was previously in the CONTINGENT APPROVAL section as voted by the BSL3 subcommittee. The PI has submitted her response to the BSL3 subcommittee review which is no longer functioning. This is the first time the main IBC will be reviewing the protocol.

III. Contingent Approvals: The following protocols were determined CONTINGENT APPROVAL with Modifications Required by unanimous vote. **See section IV New Protocols.**

IV. TABLED with Modifications Required: Clinical Trial Update

The sponsors of both clinical trials are requesting Biosafety Protocols. The committee determined more time was required to adequately review the protocols and both were **TABLED with MODIFICATIONS REQUIRED** by unanimous vote. Reviewer comments in addition to the Chemical Hygiene and Lab Inspection Forms have been sent to Dr. Cingam. New information has been reported that Dr. Ellen Friday's Biorepository Operations Lab will be used to defrost the treatment and prepare patient blood samples for shipping. The LSUHS IRB has approved both clinical trials.

B26-009 – Dr. Shashank Cingam/Hematology/Oncology – Clinical Trial: A Phase 3 Study of a arlocabtagene autoleucel, a GPRC5D-directed CAR T Cell Therapy (Quintessential 2 CA 088 clinical trial) in Participants with Relapsed or Refractory Multiple Myeloma and Refractory to Lenalidomide

B26-010 – Dr. Shashank Cingam/Hematology/Oncology – Clinical Trial: A phase 2, open-label, multicenter study of MB-105 in patients with CD5 positive (CD5+) relapsed / refractory T-cell lymphoma (r/r TCL).

Complete reviews for both protocols above were sent to the PI. All protocol documents and responses to the reviewer comments were submitted and approved by both reviewers and the IBC Chair.

V. Terminations: None

VI. OLD Business: None

VII. NEW Business: Modifications

B25-005 – Dr. Stephanie Ander/Microbiology – BSL2 The PI is requesting addition of Sindbis/MADV. Chimeric Sindbis/MADV is highly attenuated in animal models and proposed as a vaccine candidate. See attached.

B26-006 – Dr. David Morgens/Microbiology -Room Addition; see attached.

VIII. Annual Renewals: The Chairman recommends **APPROVAL** for all complete renewal/updates. Incomplete renewals will be **CONTIGENTLY APPROVED** until the *necessary* documents are submitted. (*Denotes a Conflict).

No annual renewals this month.

IX. Non-responder Annual Renewals: Dr. Vanchiere/Pediatrics has not submitted his 2025 annual renewal.

X. ADD/DELETE MEMOS: Training is complete for the following:

B21-001 – Dr. Oren Rom/Pathology
ADD: Huang, Postdoc; training complete.
B23-003 – Dr. Sungho Lee/Neurosurgery
ADD: Chang, RA; training complete
B26-008 – Dr. Khalid El Saafien/Physiology
ADD: Salman Postdoc, and Navarro R.A.; training complete.

Contingent ADD Memos:
B21-002 Dr. Rom/Pathology
ADD: Christopher Vance, Resident **(training incomplete)**

XI. Adjourn: